Disclosed are imidazopyridazinyl compounds of Formula (I): (I) or pharmaceutically salts and prodrugs thereof wherein R is Calkenyl or a cyclic group and R and R are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition such as for example cancer and pharmaceutical compositions comprising such compounds.